As of first of January 2022, StemTherapy and MultiPark have decided to merge the former iPSC, CRISPR and vector platforms into the new Cell and Gene Therapy Core. 

The Cell and Gene Therapy core is an open-access infrastructure and our services include AAV and LV vector production, iPS reprogramming, iPS-edits and CRISPR experimental designs. The core is open to members of MultiPark as well as the SCC, and national and international users.

Go to the Cell and Gene Therapy Core website.